Pneumococcal Disease: Recommended vaccinations
  General recommendation
  Recommendation for specific groups only
  Catch-up (e.g. if previous doses missed)
 
Vaccination not funded by the National Health system
 
Mandatory vaccination
MonthsYears
2345610111213141518251216171850596064657585≥ 86
Austria
PCV
PCV
PCV1
PCV15 or 20 and PPSV23
Belgium
PCV13 or PCV 15
PCV13 or PCV 15
PCV13 or PCV 15
PCV202
PCV203
Bulgaria
PCV
PCV
PCV4
PCV13+PPSV235
Croatia
PCV6
PCV6
PCV6
Cyprus
PCV
PCV
PCV7
PPSV238
PPSV239
Czechia
PCV13
PCV13
PCV13
PCV or PPSV2310
PCV13+PPSV2311
Denmark
PCV13
PCV13
PCV13
Estonia
PCV13+PPSV2312
Finland
PCV10
PCV10
PCV10
Pnc13
France
PCV13
PCV13
PCV13
PCV2014
Germany
PCV13 or PCV 15
PCV13 or PCV 15
PCV13 or PCV 15
PCV13/15+PPSV2315
PCV2016
PCV2017
Greece
PCV13 or PCV 15
PCV13 or PCV 15
PCV13 or PCV 15
PCV13 or PCV 15
PCV13 or PCV 15
PCV+PPSV2318
PCV20
PCV20
Hungary
PCV15
PCV15
PCV15
PCV20
Iceland
PCV15
PCV15
PCV15
PPSV23/PCV2019
Ireland
PCV13
PCV13
PCV13
PPSV2320
PPSV2321
Italy
PCV
PCV
PCV
PCV13+PPSV2322
Latvia
PCV
PCV
PCV
Liechtenstein
PCV13
PCV13
PCV13
Lithuania
PCV
PCV
PCV23
Luxembourg
PCV
PCV24
PCV
PCV
PCV25
PCV26
PCV27
Malta
PCV
PCV
PCV
Netherlands
PCV10
PCV10
PCV10
PPSV2328
Norway
PCV13
PCV13
PCV13
PPSV2329
Poland
PCV
PCV
PCV
PCV
Portugal
PCV1330
PCV13
PCV13
PPSV2331
Romania
PCV
PCV
PCV
Slovakia
PCV13
PCV13
PCV13
PCV32
Slovenia
PCV1333
PCV13
PCV13
PCV13+PPSV2334
Spain
PCV35
PCV35
PCV35
PPSV23 / PCV+PPSV2336
PPSV2337
Sweden
PCV
PCV
PCV
PPSV2338

Footnotes:

  1. Minimum interval of 7 months after the second dose
  2. Preferred scheme: one of PCV20 for alternative schemes based on past pneumo vaccination refer to https://www.health.belgium.be/fr/avis-9674-vaccination-antipneumococcique-adultes
  3. Preferred scheme: one of PCV20 for alternative schemes based on past pneumo vaccination refer to https://www.health.belgium.be/fr/avis-9674-vaccination-antipneumococcique-adultes
  4. Not earlier than 6 months after the previous dose
  5. PCV13 is given starting from 50 years. The scheme is completed with PPSV23 in 65 years and older
  6. Introduced in 2019
  7. catch-up possible until 6 years if previous recommended doses were missed
  8. vaccines only given on specific indications
  9. No revaccination recommended.
  10. Any PCV or PPSV23. Vaccination is especially recommended for people with chronic lung disease (includes moderate and severe bronchial asthma), with long-term medical treatment; persons with heart disease and/or large vessels with long-term systemic medical treatment, such as hypertension; people with chronic kidney and liver disease; patients with diabetes mellitus; patients with an immune disorder system (eg patients with immunosuppressive treatment (steroids, HIV infections, etc.) and asplenia / hyposplenia; patients with anticancer treatment; patients before / after solid organ and / or bone marrow transplantation; people with severe obesity (BMI over 40 kg / m2) and persons over 65 years of age.
  11. https://www.vakcinace.eu/data/files/downloads/ockovaci_kalendar_dospsdatem.pdf
  12. As of April 2021 pneumococcal and meningococcal vaccinations free of charge for higher-risk risk groups.
  13. for more information on pneumococcal vaccination and target groups refer to https://thl.fi/fi/web/infektiotaudit-ja-rokotukset/rokotteet-a-o/pneumokokkirokotteet
  14. From August 2023, PCV20 recommended instead of a mixed schedule PCV13+PPSV23 in adults from 18 years of age for individuals at risk. see https://www.has-sante.fr/jcms/p_3457419/fr/strategie-de-vaccination-contre-les-infections-a-pneumocoque-place-du-vaccin-pneumococcique-polyosidique-conjugue-20-valent-adsorbe-chez-l-adulte for more information
  15. see https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2023/Ausgaben/20_23.pdf?__blob=publicationFile for detail on targeted groups
  16. see recommendation details for at-risk groups where vaccination is recommended https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2023/Ausgaben/39_23.pdf?__blob=publicationFile
  17. change of recommendations in Sept 2023 moving away from PPSV23. For individuals previously vaccinated with PPSV23, a dose of PCV20 is recommended in an interval of at least 6 years after PPSV23 dose. for more details refer to https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2023/Ausgaben/39_23.pdf?__blob=publicationFile for more information
  18. PPSV is recommended in addition to PCV13 or PCV15 at least 2 months after the last dose of PCV13 in subjects > 2 years with an increased risk of disease from pneumococcal infections. A booster dose of PPSV23 is recommended 5 years after the first dose
  19. One dose of polysaccharide vaccine or 20-valent protein-based vaccine if polysaccharide vaccine is not available or according to medical advice. If individuals have previously received a pneumococcal vaccine before their 60th birthday, vaccination is recommended according to https://assets.ctfassets.net/8k0h54kbe6bj/1yjQz7UQApSJyLgbOZS3DI/a937283df2c90b47bfb414d5e56dd5c2/Leidbeiningar_um_notkun_boluefna_gegn_pneumokokkum-2019.pdf
  20. Please refer to https://www.hse.ie/eng/health/immunisation/pubinfo/adult/pneumo/#Who%20should%20be%20vaccinated%20with%20PPV23%20Pneumococcal%20vaccine? for a full listing of people in at-risk groups
  21. The vaccine is free of charge, but administration fees may be charged to patient (based on income and eligibility for free healthcare). Please refer to https://www.hse.ie/eng/health/immunisation/pubinfo/adult/pneumo/#Who%20should%20be%20vaccinated%20with%20PPV23%20Pneumococcal%20vaccine? for a full listing of people in at-risk groups
  22. one dose of PCV13 at 65 years and one dose PPSV after at least 8 weeks
  23. Can be administered concomitantly with MMR
  24. For premature infants (born before 33 weeks) or with a birthweight <1500g, a 3+1 schedule is recommended
  25. For those not previously vaccinated with an increased risk of severe disease.
  26. for those at increased risk of complications or severe disease
  27. For people aged 65 years of age, update to the pneumococcal recommendations based on prior vaccination. please refer to the full recommendation available here: https://sante.public.lu/dam-assets/fr/espace-professionnel/recommandations/conseil-maladies-infectieuses/infection-pneumocoques/csmi-recommandation-vaccination-pcv-personnes-agees-ou-a-risque.pdf
  28. For information refer to https://www.rivm.nl/pneumokokken/pneumokokkenprik
  29. One dose if not vaccinated in the previous 10 years. Reimbursed for some at-risk groups. https://www.fhi.no/nettpub/vaksinasjonsveilederen-for-helsepersonell/vaksiner-mot-de-enkelte-sykdommene/pneumokokkvaksinasjon---veileder-fo/
  30. https://www.dgs.pt/paginas-de-sistema/saude-de-a-a-z/programa-nacional-de-vacinacao/vacinas-do-pnv/infecoes-por-streptococcus-pneumoniae.aspx
  31. for information on the full pneumococcal programme refer to https://www.dgs.pt/normas-orientacoes-e-informacoes/normas-e-circulares-normativas/norma-n-0112015-de-23062015-pdf.aspx
  32. Recommended to all. Mandatory to persons residing in social care facilities
  33. https://nijz.si/wp-content/uploads/2019/05/cepljenje_s_konj_pnevmo_za_otroke_2022_2.pdf
  34. PCV and PPSV23 recommended, self-paid
  35. For recommendations in children and adults with high risk conditions Please refer to https://www.sanidad.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/programasDeVacunacion/riesgo/home.htm
  36. For recommendations in children and adults with high risk conditions, refer to: https://www.sanidad.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/programasDeVacunacion/riesgo/home.htm
  37. Additional information https://www.sanidad.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/programasDeVacunacion/docs/Vacunacion_poblacion_adulta.pdf
  38. https://www.folkhalsomyndigheten.se/smittskydd-beredskap/vaccinationer/nationella-vaccinationsprogram/program-for-riskgrupper/